BioLine Rx (BioLine Rx) Operating Cash Flow per Share : $-0.38 (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Operating Cash Flow per Share?

BioLine Rx's operating cash flow per share for the three months ended in Dec. 2023 was $0.07. BioLine Rx's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.38.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 36.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 38.10% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 28.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for BioLine Rx's Operating Cash Flow per Share or its related term are showing as below:

BLRX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 6.8 Med: 29.7 Max: 45.8
Current: 36.6

During the past 13 years, BioLine Rx's highest 3-Year average Operating Cash Flow per Share Growth Rate was 45.80% per year. The lowest was 6.80% per year. And the median was 29.70% per year.

BLRX's 3-Year OCF Growth Rate is ranked better than
84.14% of 1236 companies
in the Biotechnology industry
Industry Median: 3.55 vs BLRX: 36.60

BioLine Rx Operating Cash Flow per Share Historical Data

The historical data trend for BioLine Rx's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Operating Cash Flow per Share Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.32

-1.38

-0.53

-0.51

-0.35

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.09	-0.13	-0.16	-0.16	0.07

Competitive Comparison of BioLine Rx's Operating Cash Flow per Share

For the Biotechnology subindustry, BioLine Rx's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Price-to-Operating-Cash-Flow falls into.

BioLine Rx Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

BioLine Rx's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-22.608	/	64.224
	=	-0.35

BioLine Rx's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	4.991	/	71.895
	=	0.07

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38

BioLine Rx Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.